LETTERS TO THE EDITOR

Storiform-type Malignant Histiocytoma of the Lung

To the editor: Soft tissue sarcomas are neoplasms which establish themselves on structures of mesodermic origin. The most common histological variant in adults is the malignant fibrous histiocytoma (MFH), though this rarely occurs in the lung.1-4 Malignant desmoplastic mesothelioma, and all other types of pulmonary sarcoma.1-4

Radiographically, MFHs tend to be solitary, noncavitated and peripheral, located most often in the middle or inferior lobe, as in this case, and they frequently affect the pleura and are associated with pleural effusion.1-4 The typical tomographic image is of a large, well-circumscribed tumor, neither cavitated nor calcified, located peripherally and without hilar or mediastinal adenopathy.1 Bronchoscopy and fine needle aspiration are of limited value in the differential diagnosis,2 making it often necessary to perform a thoracotomy in order to reach the definitive diagnosis, as was true in this patient. Microscopic inspection shows a malignant neoplasm of spiculated cells. Unfortunately there exist no specific immunohistological markers, though similar sarcomas can be ruled out by means of specific immunohistochemical assays. Histological variants are the storiform, pleomorphic, myxoid, inflammatory, giant cell, and angiomatoid variants, with the majority of pulmonary MFHs being of a mixed storiform-pleomorphic variety.

Resective surgery is the standard, essential treatment. It has been noted that if treatment is limited to biopsy or partial resection, the survival rate averages between 9-10 months,1 whereas if the surgery is intended to be curative, the disease-free survival improves, with 20% alive at 5 years.1,2 Magne et al3 have studied survival rates for cases of primary pulmonary sarcoma and observed that rates are significantly higher when total resection is performed compared with partial surgery (47 vs 6 months). Furthermore, survival longer than 5 years has been obtained with complete resections of recurrences, early diagnosis being essential in these instances; hence the importance of periodic check-ups. Most authors have not been able to demonstrate the usefulness of radiotherapy in treatment, though Lee et al4 achieved extended survival by applying 5400 cGy prior to surgery. Systemic chemotherapy is used for metastatic cases but has not succeeded in improving survival.1,4

Systemic metastases, primarily cerebral, are common, which may be due to the high incidence of vascular invasion at the time of diagnosis.1 The prognostic factors involved in pulmonary location are not well understood, although, in general terms, total resection of the macroscopic disease, age above 50 years, the tumor grade, the histological variant, the size of the tumor, and the number of distant metastases at the time of diagnosis have been described as prognostic factors in MFH.5 In the pulmonary cases that have been described, nearly all patients with long survival have been negative for node involvement, as was the case with our own patient; only Yousuf and Hochholzer6 have described a patient who survived for 36 months with mediastinal adenopathy. No clear relation between survival and pulmonary histology has been
LETTERS TO THE EDITOR

established, possibly because of the predominance of the mixed storiform-pleomorphic subtype.

A. Ríos Zambudio,* M.J. Roca Calvo,*
and L.A Polo García

*Departamento de Cirugía, Servicio de Cirugía Torácica, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Servicio de Anatomía Patológica, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.